<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340021</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>29</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Risk of COVID-19 in Children throughout the Pandemic and the Role of Vaccination: A Narrative Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">989</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12090989</ELocationID><Abstract><AbstractText>At the beginning of the coronavirus disease 2019 (COVID-19) pandemic, persons ≥65 years of age and healthcare personnel represented the most vulnerable groups with respect to risk of infection, severe illness, and death. However, as the pandemic progressed, there was an increasingly detrimental effect on young children and adolescents. Severe disease and hospitalization increased over time in pediatric populations, and containment measures created substantial psychosocial, educational, and economic challenges for young people. Vaccination of children against COVID-19 has been shown to reduce severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and severe outcomes in pediatric populations and may also help to prevent the spread of variants of concern and improve community immunity. This review discusses the burden of COVID-19 on children throughout the pandemic, the role of children in disease transmission, and the impact of COVID-19 vaccination.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, UNC School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Kanecia O</ForeName><Initials>KO</Initials><AffiliationInfo><Affiliation>Duke Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tartof</LastName><ForeName>Sara Y</ForeName><Initials>SY</Initials><Identifier Source="ORCID">0000-0003-2336-8476</Identifier><AffiliationInfo><Affiliation>Department of Research &amp; Evaluation, Kaiser Permanente Southern California, Pasadena, CA 91107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLaughlin</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Pfizer Vaccines, 500 Arcola Rd, Collegeville, PA 19426, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pather</LastName><ForeName>Shanti</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>BioNTech SE, An der Goldgrube 12, 55131 Mainz, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 vaccines</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">children</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">pediatric</Keyword></KeywordList><CoiStatement>D.J.W. has received consulting fees from Pfizer, Germitac, PDI, and BD in relation to vaccines and disinfection products, was a member of a Data Safety Monitoring Board/Advisory Board at GlaxoSmithKline, and is a member on the board at Society for Healthcare Epidemiology of America (SHEA). K.O.Z. receives salary support from the US National Institutes of Health (NIH) and the US Food and Drug Administration (FDA) through Duke University, has received an honorarium from Pediatric Grand Rounds (Ohio State University) and for an NMA COVID-19 report on provider perspectives, and is on the membership committee for USP. S.Y.T. has received grants from Pfizer Inc., paid directly to the institution, for work unrelated to this manuscript. J.M.M. is an employee and holds stock options at Pfizer Inc. S.P. is an employee of BioNTech SE.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340021</ArticleId><ArticleId IdType="pmc">PMC11435672</ArticleId><ArticleId IdType="doi">10.3390/vaccines12090989</ArticleId><ArticleId IdType="pii">vaccines12090989</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Buonsenso D., Espuny Pujol F., Munblit D., Pata D., McFarland S., Simpson F.K. Clinical characteristics, activity levels and mental health problems in children with long coronavirus disease: A survey of 510 children. Future Microbiol. 2022;17:577–588. doi: 10.2217/fmb-2021-0285.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb-2021-0285</ArticleId><ArticleId IdType="pmc">PMC9248023</ArticleId><ArticleId IdType="pubmed">35360923</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura T., Ito J., Uriu K., Zahradnik J., Kida I., Nasser H., Shofa M., Oda Y., Lytras S., Nao N., et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. bioRxiv. 2022 doi: 10.1038/s41467-023-38435-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-38435-3</ArticleId><ArticleId IdType="pmc">PMC10187524</ArticleId><ArticleId IdType="pubmed">37193706</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Initial Risk Evaluation of JN.1, 19 December 2023.  [(accessed on 26 April 2024)].  Available online:  https://www.who.int/docs/default-source/coronaviruse/18122023_jn.1_ire_clean.pdf?sfvrsn=6103754a_3.</Citation></Reference><Reference><Citation>Kaku Y., Uriu K., Kosugi Y., Okumura K., Yamasoba D., Uwamino Y., Kuramochi J., Sadamasu K., Yoshimura K., Asakura H., et al. Virological characteristics of the SARS-CoV-2 KP.2 variant. Lancet Infect. Dis. 2024;24:e416. doi: 10.1016/S1473-3099(24)00298-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(24)00298-6</ArticleId><ArticleId IdType="pubmed">38782005</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku Y., Yo M.S., Tolentino J.E., Uriu K., Okumura K., Ito J., Sato K. Virological characteristics of the SARS-CoV-2 KP.3, LB.1, and KP.2.3 variants. Lancet Infect. Dis. 2024;24:e482–e483. doi: 10.1016/S1473-3099(24)00415-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(24)00415-8</ArticleId><ArticleId IdType="pubmed">38945150</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabelli A.M., Peacock T.P., Thorne L.G., Harvey W.T., Hughes J., COVID-19 Genomics UK Consortium. Peacock S.J., Barclay W.S., de Silva T.I., Towers G.J., et al. SARS-CoV-2 variant biology: Immune escape, transmission and fitness. Nat. Rev. Microbiol. 2023;21:162–177. doi: 10.1038/s41579-022-00841-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00841-7</ArticleId><ArticleId IdType="pmc">PMC9847462</ArticleId><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>Delahoy M.J., Ujamaa D., Taylor C.A., Cummings C., Anglin O., Holstein R., Milucky J., O’Halloran A., Patel K., Pham H., et al. Comparison of Influenza and Coronavirus Disease 2019-Associated Hospitalizations among Children Younger Than 18 Years Old in the United States: FluSurv-NET (October–April 2017–2021) and COVID-NET (October 2020–September 2021) Clin. Infect. Dis. 2023;76:e450–e459. doi: 10.1093/cid/ciac388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac388</ArticleId><ArticleId IdType="pmc">PMC9129156</ArticleId><ArticleId IdType="pubmed">35594564</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang Y.C., Lin K.P., Wang L.A., Yeh T.K., Liu P.Y. The Impact of the COVID-19 Pandemic on Respiratory Syncytial Virus Infection: A Narrative Review. Infect. Drug Resist. 2023;16:661–675. doi: 10.2147/IDR.S396434.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IDR.S396434</ArticleId><ArticleId IdType="pmc">PMC9897071</ArticleId><ArticleId IdType="pubmed">36743336</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuhara J., Masuda K., Aikawa T., Shirasu T., Takagi H., Lee S., Kuno T. Myopericarditis After COVID-19 mRNA Vaccination Among Adolescents and Young Adults: A Systematic Review and Meta-analysis. JAMA Pediatr. 2023;177:42–52. doi: 10.1001/jamapediatrics.2022.4768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2022.4768</ArticleId><ArticleId IdType="pmc">PMC9856920</ArticleId><ArticleId IdType="pubmed">36469338</ArticleId></ArticleIdList></Reference><Reference><Citation>Galagali P.M., Kinikar A.A., Kumar V.S. Vaccine Hesitancy: Obstacles and Challenges. Curr. Pediatr. Rep. 2022;10:241–248. doi: 10.1007/s40124-022-00278-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40124-022-00278-9</ArticleId><ArticleId IdType="pmc">PMC9546747</ArticleId><ArticleId IdType="pubmed">36245801</ArticleId></ArticleIdList></Reference><Reference><Citation>Aw J., Seng J.J.B., Seah S.S.Y., Low L.L. COVID-19 Vaccine Hesitancy-A Scoping Review of Literature in High-Income Countries. Vaccines. 2021;9:900. doi: 10.3390/vaccines9080900.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9080900</ArticleId><ArticleId IdType="pmc">PMC8402587</ArticleId><ArticleId IdType="pubmed">34452026</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Updated Working Definitions and Primary Actions for SARS-CoV-2 Variants.  [(accessed on 20 August 2024)].  Available online:  https://www.who.int/publications/m/item/updated-working-definitions-and-primary-actions-for--sars-cov-2-variants.</Citation></Reference><Reference><Citation>World Health Organization  XBB.1.5 Rapid Risk Assessment, 11 January 2023.  [(accessed on 20 August 2024)].  Available online:  https://www.who.int/docs/default-source/coronaviruse/11jan2023_xbb15_rapid_risk_assessment.pdf.</Citation></Reference><Reference><Citation>World Health Organization  Statement on the Fifteenth Meeting of the IHR (2005) Emergency Committee on the COVID-19 Pandemic.  [(accessed on 20 August 2024)].  Available online:  https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic.</Citation></Reference><Reference><Citation>World Health Organization  Tracking SARS-CoV-2 Variants.  [(accessed on 20 August 2024)].  Available online:  https://www.who.int/activities/tracking-SARS-CoV-2-variants.</Citation></Reference><Reference><Citation>World Health Organization  Weekly Epidemiological Update on COVID-19—22 June 2023.  [(accessed on 20 August 2024)].  Available online:  https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---22-june-2023.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  COVID-19 Activity Increases as Prevalence of JN.1 Variant Continues to Rise.  [(accessed on 20 August 2024)]; Available online:  https://www.cdc.gov/ncird/whats-new/JN.1-update-2024-01-05.html.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  COVID Data Tracker: Weighted and Nowcast Estimates in United States for 2-Week Periods in 4/28/2024–8/17/2024.  [(accessed on 20 August 2024)]; Available online:  https://covid.cdc.gov/covid-data-tracker/#variant-proportions.</Citation></Reference><Reference><Citation>Uriu K., Ito J., Kosugi Y., Tanaka Y.L., Mugita Y., Guo Z., Hinay A.A., Jr., Putri O., Kim Y., Shimizu R., et al. Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant. Lancet Infect. Dis. 2023;23:E460–E461. doi: 10.1016/S1473-3099(23)00575-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00575-3</ArticleId><ArticleId IdType="pubmed">37734391</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Iketani S., Li Z., Liu L., Guo Y., Huang Y., Bowen A.D., Liu M., Wang M., Yu J., et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186:279–286.e278. doi: 10.1016/j.cell.2022.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.12.018</ArticleId><ArticleId IdType="pmc">PMC9747694</ArticleId><ArticleId IdType="pubmed">36580913</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue C., Song W., Wang L., Jian F., Chen X., Gao F., Shen Z., Wang Y., Wang X., Cao Y. Enhanced transmissibility of XBB.1.5 is contributed by both strong ACE2 binding and antibody evasion. bioRxiv. 2023 doi: 10.1101/2023.01.03.522427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.01.03.522427</ArticleId><ArticleId IdType="pmc">PMC9897732</ArticleId><ArticleId IdType="pubmed">36746173</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasoba D., Uriu K., Plianchaisuk A., Kosugi Y., Pan L., Zahradnik J., Genotype to Phenotype Japan Consortium. Ito J., Sato K. Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant. Lancet Infect. Dis. 2023;23:655–656. doi: 10.1016/S1473-3099(23)00278-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00278-5</ArticleId><ArticleId IdType="pmc">PMC10156138</ArticleId><ArticleId IdType="pubmed">37148902</ArticleId></ArticleIdList></Reference><Reference><Citation>covSPECTRUM  BA.4.6.  [(accessed on 20 August 2024)].  Available online:  https://cov-spectrum.org/explore/World/AllSamples/from%3D2022-12-01%26to%3D2023-03-10/variants?dateSubmittedFrom=2022-12-01&amp;dateSubmittedTo=2023-03-10&amp;nextcladePangoLineage=ba.4.6&amp;.</Citation></Reference><Reference><Citation>covSPECTRUM  XBB.1.5.  [(accessed on 20 August 2024)].  Available online:  https://cov-spectrum.org/explore/World/AllSamples/from%3D2022-12-01%26to%3D2023-03-10/variants?dateSubmittedFrom=2022-12-01&amp;dateSubmittedTo=2023-03-10&amp;nextcladePangoLineage=XBB.1.5&amp;.</Citation></Reference><Reference><Citation>World Health Organization  Initial Risk Evaluation of BA.2.86 and Its Sublineages, 21 November 2023.  [(accessed on 20 August 2024)].  Available online:  https://www.who.int/docs/default-source/coronaviruse/21112023_ba.2.86_ire.pdf.</Citation></Reference><Reference><Citation>Wolter N., Jassat W., Walaza S., Welch R., Moultrie H., Groome M.J., Amoako D.G., Everatt J., Bhiman J.N., Scheepers C., et al. Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa. Nat. Commun. 2022;13:5860. doi: 10.1038/s41467-022-33614-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33614-0</ArticleId><ArticleId IdType="pmc">PMC9531215</ArticleId><ArticleId IdType="pubmed">36195617</ArticleId></ArticleIdList></Reference><Reference><Citation>CDR Heather Scobie  Update on Current Epidemiology of the COVID-19 Pandemic and SARS-CoV-2 Variants.  [(accessed on 20 August 2024)]; Available online:  https://www.fda.gov/media/164814/download.</Citation></Reference><Reference><Citation>Zheng Q.T., Mazarakis N., Nguyen J., Higgins R.A., Anderson J., Anh Ha Do L., Burgner D.P., Curtis N., Steer A.C., Mulholland K., et al. Comparison of antibody responses to SARS-CoV-2 variants in Australian children. medRxiv. 2022 doi: 10.1101/2022.08.12.22278705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.12.22278705</ArticleId><ArticleId IdType="pmc">PMC9700848</ArticleId><ArticleId IdType="pubmed">36434068</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Statement on the Antigen Composition of COVID-19 Vaccines.  [(accessed on 20 August 2024)].  Available online:  https://www.who.int/news/item/18-05-2023-statement-on-the-antigen-composition-of-covid-19-vaccines.</Citation></Reference><Reference><Citation>United States Food and Drug Administration  Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2023.  [(accessed on 20 August 2024)]; Available online:  https://web.archive.org/web/20240109053208/https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccines-use-united-states-beginning-fall-2023.</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control (ECDC) and European Medicines Agency (EMA)  ECDC-EMA Statement on Updating COVID-19 Vaccines Composition for New SARS-CoV-2 Virus Variants.  [(accessed on 20 August 2024)].  Available online:  https://www.ema.europa.eu/en/documents/other/ecdc-ema-statement-updating-covid-19-vaccines-composition-new-sars-cov-2-virus-variants_en.pdf.</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration  FDA Takes Action on Updated mRNA COVID-19 Vaccines to Better Protect against Currently Circulating Variants.  [(accessed on 20 August 2024)]; Available online:  https://www.fda.gov/news-events/press-announcements/fda-takes-action-updated-mrna-covid-19-vaccines-better-protect-against-currently-circulating.</Citation></Reference><Reference><Citation>Regan J.J., Moulia D.L., Link-Gelles R., Godfrey M., Mak J., Najdowski M., Rosenblum H.G., Shah M.M., Twentyman E., Meyer S., et al. Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged &gt;/=6 Months: Recommendations of the Advisory Committee on Immunization Practices-United States, September 2023. MMWR Morb. Mortal. Wkly. Rep. 2023;72:1140–1146. doi: 10.15585/mmwr.mm7242e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7242e1</ArticleId><ArticleId IdType="pmc">PMC10602621</ArticleId><ArticleId IdType="pubmed">37856366</ArticleId></ArticleIdList></Reference><Reference><Citation>Panagiotakopoulos L., Godfrey M., Moulia D.L., Link-Gelles R., Taylor C.A., Chatham-Stephens K., Brooks O., Daley M.F., Fleming-Dutra K.E., Wallace M. Use of an Additional Updated 2023–2024 COVID-19 Vaccine Dose for Adults Aged &gt;/=65 Years: Recommendations of the Advisory Committee on Immunization Practices-United States, 2024. MMWR Morb. Mortal. Wkly. Rep. 2024;73:377–381. doi: 10.15585/mmwr.mm7316a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7316a4</ArticleId><ArticleId IdType="pmc">PMC11065461</ArticleId><ArticleId IdType="pubmed">38662708</ArticleId></ArticleIdList></Reference><Reference><Citation>United States Food and Drug Administration  Vaccines and Related Biological Products Advisory Committee June 5, 2024 Meeting Announcement.  [(accessed on 20 August 2024)]; Available online:  https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-5-2024-meeting-announcement.</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration  Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2024.  [(accessed on 20 August 2024)]; Available online:  https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccines-use-united-states-beginning-fall-2024.</Citation></Reference><Reference><Citation>Gayed J., Diya O., Lowry F.S., Xu X., Bangad V., Mensa F., Zou J., Xie X., Hu Y., Lu C., et al. Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals &gt;/=12 Years Old: A Phase 2/3 Trial. Vaccines. 2024;12:118. doi: 10.3390/vaccines12020118.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12020118</ArticleId><ArticleId IdType="pmc">PMC10893482</ArticleId><ArticleId IdType="pubmed">38400102</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias S., McGhee N., Whatley J.L., Essink B., Brosz A., Tomassini J.E., Girard B., Edwards D.K., Wu K., Nasir A., et al. Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines. J. Infect. Dis. 2024;230:e279–e286. doi: 10.1093/infdis/jiae067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiae067</ArticleId><ArticleId IdType="pmc">PMC11326827</ArticleId><ArticleId IdType="pubmed">38349280</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Guo Y., Bowen A., Mellis I.A., Valdez R., Gherasim C., Gordon A., Liu L., Ho D.D. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants. bioRxiv. 2023 doi: 10.1101/2023.11.26.568730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.11.26.568730</ArticleId><ArticleId IdType="pmc">PMC10948033</ArticleId><ArticleId IdType="pubmed">38377995</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Mellis I.A., Guo Y., Gherasim C., Valdez R., Gordon A., Liu L., Ho D.D. Robust SARS-CoV-2 Neutralizing Antibodies Sustained through Three Months Post XBB.1.5 mRNA Vaccine Booster. bioRxiv. 2024 doi: 10.1101/2024.02.16.580687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.02.16.580687</ArticleId><ArticleId IdType="pubmed">39208800</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Staropoli I., Michel V., Lemoine F., Donati F., Prot M., Porrot F., Guivel-Benhassine F., Jeyarajah B., Brisebarre A., et al. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion. bioRxiv. 2024 doi: 10.1038/s41467-024-46490-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-46490-7</ArticleId><ArticleId IdType="pmc">PMC10938001</ArticleId><ArticleId IdType="pubmed">38480689</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain S., Kumar S., Lai L., Linderman S., Malik A.A., Ellis M.L., Godbole S., Solis D., Sahoo M.K., Bechnak K., et al. XBB.1.5 monovalent booster improves antibody binding and neutralization against emerging SARS-CoV-2 Omicron variants. bioRxiv. 2024 doi: 10.1101/2024.02.03.578771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.02.03.578771</ArticleId></ArticleIdList></Reference><Reference><Citation>He X., Jiang J., Li G., Liu J., Gan J., Zhou L., Bai C., Zi Q., Mou X., Zeng S., et al. Heterogeneous hybrid immunity against Omicron variant JN.1 at 11 months following breakthrough infection. bioRxiv. 2024 doi: 10.1038/s41392-024-01898-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-024-01898-x</ArticleId><ArticleId IdType="pmc">PMC11258359</ArticleId><ArticleId IdType="pubmed">39025834</ArticleId></ArticleIdList></Reference><Reference><Citation>UNICEF  COVID-19 Confirmed Cases and Deaths Age- and Sex-Disaggregated Data.  [(accessed on 20 August 2024)].  Available online:  https://data.unicef.org/resources/covid-19-confirmed-cases-and-deaths-dashboard/</Citation></Reference><Reference><Citation>Vandenberg O., Martiny D., Rochas O., van Belkum A., Kozlakidis Z. Considerations for diagnostic COVID-19 tests. Nat. Rev. Microbiol. 2021;19:171–183. doi: 10.1038/s41579-020-00461-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00461-z</ArticleId><ArticleId IdType="pmc">PMC7556561</ArticleId><ArticleId IdType="pubmed">33057203</ArticleId></ArticleIdList></Reference><Reference><Citation>Han A.X., Toporowski A., Sacks J.A., Perkins M.D., Briand S., van Kerkhove M., Hannay E., Carmona S., Rodriguez B., Parker E., et al. SARS-CoV-2 diagnostic testing rates determine the sensitivity of genomic surveillance programs. Nat. Genet. 2023;55:26–33. doi: 10.1038/s41588-022-01267-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-022-01267-w</ArticleId><ArticleId IdType="pmc">PMC9839449</ArticleId><ArticleId IdType="pubmed">36624344</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolopoulou G.B., Maltezou H.C. COVID-19 in Children: Where do we Stand? Arch. Med. Res. 2022;53:1–8. doi: 10.1016/j.arcmed.2021.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2021.07.002</ArticleId><ArticleId IdType="pmc">PMC8257427</ArticleId><ArticleId IdType="pubmed">34311990</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobbs C.V., Drobeniuc J., Kittle T., Williams J., Byers P., Satheshkumar P.S., Inagaki K., Stephenson M., Kim S.S., Patel M.M., et al. Estimated SARS-CoV-2 Seroprevalence among Persons Aged &lt;18 Years-Mississippi, May–September 2020. MMWR Morb. Mortal. Wkly. Rep. 2021;70:312–315. doi: 10.15585/mmwr.mm7009a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7009a4</ArticleId><ArticleId IdType="pmc">PMC7948937</ArticleId><ArticleId IdType="pubmed">33661862</ArticleId></ArticleIdList></Reference><Reference><Citation>Farronato M., Dolci C., Boccalari E., Izadi S., Salvatierra Rios L.H., Festa M., Panetta V., De Vito D., Tartaglia G.M. Serological profile of children and young adults with at least one SARS-CoV-2 positive cohabitant: An observational study. Int. J. Environ. Res. Public Health. 2021;18:1488. doi: 10.3390/ijerph18041488.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18041488</ArticleId><ArticleId IdType="pmc">PMC7914765</ArticleId><ArticleId IdType="pubmed">33557402</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices  Epidemiology of COVID-19 in Children Aged 5–11 Years.  [(accessed on 20 August 2024)]; Available online:  https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-11-2-3/03-COVID-Jefferson-508.pdf.</Citation></Reference><Reference><Citation>Anderson E.J., Campbell J.D., Creech C.B., Frenck R., Kamidani S., Munoz F.M., Nachman S., Spearman P. Warp speed for coronavirus disease 2019 (COVID-19) vaccines: Why are children stuck in neutral? Clin. Infect. Dis. 2021;73:336–340. doi: 10.1093/cid/ciaa1425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1425</ArticleId><ArticleId IdType="pmc">PMC7543330</ArticleId><ArticleId IdType="pubmed">32945335</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Health Security Agency  Winter Coronavirus (COVID-19) Infection Study: Estimates of Epidemiological Characteristics, England and Scotland: 2023 to 2024.  [(accessed on 20 August 2024)]; Available online:  https://www.gov.uk/government/statistics/winter-coronavirus-covid-19-infection-study-estimates-of-epidemiological-characteristics-england-and-scotland-2023-to-2024.</Citation></Reference><Reference><Citation>covSPECTRUM  United Kingdom XBB* from 2023-11-14 to 2024-03-03.  [(accessed on 20 August 2024)].  Available online:  https://cov-spectrum.org/explore/United%20Kingdom/AllSamples/from%3D2023-11-14%26to%3D2024-03-03/variants?nextcladePangoLineage=XBB*&amp;.</Citation></Reference><Reference><Citation>covSPECTRUM  United Kingdom JN.1 from 2023-11-14 to 2024-03-03.  [(accessed on 20 August 2024)].  Available online:  https://cov-spectrum.org/explore/United%20Kingdom/AllSamples/from%3D2023-11-14%26to%3D2024-03-03/variants?nextcladePangoLineage=jn.1*&amp;.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  COVID-NET: Rates of Laboratory-Confirmed COVID-19-Associated Hospitalizations, Preliminary Weekly Rates as of March 15.  [(accessed on 15 March 2024)];2024  Available online:  https://www.cdc.gov/coronavirus/2019-ncov/covidnetdashboard/de/powerbi/dashboard.html.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  COVID Data Tracker: Nowcast Projection of COVID-19 Variants for the Week Ending March 16.  [(accessed on 15 March 2024)];2024  Available online:  https://covid.cdc.gov/covid-data-tracker/#variant-proportions.</Citation></Reference><Reference><Citation>Israel Ministry of Health  The Coronavirus in Israel—A General Picture.  [(accessed on 15 March 2024)]; Available online:  https://datadashboard.health.gov.il/COVID-19/general.</Citation></Reference><Reference><Citation>covSPECTRUM  Israel Analyze Single Variant from 2024-02-11 to 2024-03-13.  [(accessed on 15 March 2024)].  Available online:  https://cov-spectrum.org/explore/Israel/AllSamples/from%3D2024-02-11%26to%3D2024-03-13/variants?&amp;.</Citation></Reference><Reference><Citation>Liguoro I., Pilotto C., Bonanni M., Ferrari M.E., Pusiol A., Nocerino A., Vidal E., Cogo P. SARS-COV-2 infection in children and newborns: A systematic review. Eur. J. Pediatr. 2020;179:1029–1046. doi: 10.1007/s00431-020-03684-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-020-03684-7</ArticleId><ArticleId IdType="pmc">PMC7234446</ArticleId><ArticleId IdType="pubmed">32424745</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewster R.C., Parsons C., Laird-Gion J., Hilker S., Irwin M., Sommerschield A., Michaelis K.A., Lam M., Parsons A., Mansbach J.M. COVID-19-associated croup in children. Pediatrics. 2022;149:e2022056492. doi: 10.1542/peds.2022-056492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2022-056492</ArticleId><ArticleId IdType="pubmed">35257175</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam M.C.Y., Lam D.S.Y. The Omicron variant of COVID-19 and its association with croup in children: A single-centre study in Hong Kong. Hong Kong Med. J. 2024;30:44–55. doi: 10.12809/hkmj2210455.</Citation><ArticleIdList><ArticleId IdType="doi">10.12809/hkmj2210455</ArticleId><ArticleId IdType="pubmed">38327165</ArticleId></ArticleIdList></Reference><Reference><Citation>Lio K., Hagiwara Y., Saito O., Ishida Y., Horikoshi Y. Seizure in children with severe acute respiratory syndrome coronavirus 2 Omicron variant infection. Pediatr. Int. 2022;64:e15255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9537988</ArticleId><ArticleId IdType="pubmed">35972066</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohta K., Okanishi T., Arai Y., Kanai S., Nakamura Y., Namba N., Maegaki Y. Febrile seizure in children with COVID-19 during the Omicron variant-predominant era: A single-center study. Brain Dev. 2024;46:28–34. doi: 10.1016/j.braindev.2023.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.braindev.2023.08.006</ArticleId><ArticleId IdType="pubmed">37661526</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Communicable Disease South Africa. Private Consultations Excess Respiratory Encounters Report, Week 15. 2022.  [(accessed on 20 August 2024)].  Available online:  https://www.nicd.ac.za/wp-content/uploads/2022/04/NICD-Private-Consultations-Excess-Respiratory-Encounters-Report-Week-15-2022.pdf.</Citation></Reference><Reference><Citation>UK Health Security Agency  SARS-CoV-2 Variants of Concern and Variants under Investigation in England. Technical Briefing 34, 14 January 2022.  [(accessed on 20 August 2024)]; Available online:  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1046853/technical-briefing-34-14-january-2022.pdf.</Citation></Reference><Reference><Citation>Vashishtha V.M., Kumar P. Conjunctival Involvement in Infants as an Unusual Symptom of Omicron XBB.1.16 Driven Surge. Indian Pediatr. 2023;60:861–862. doi: 10.1007/s13312-023-3020-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13312-023-3020-0</ArticleId><ArticleId IdType="pubmed">37818812</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Updated Risk Evaluation of JN.1, 9 February 2024.  [(accessed on 20 August 2024)].  Available online:  https://cdn.who.int/media/docs/default-source/documents/health-topics/sars/jn.1-9-february-2024.pdf?sfvrsn=9a39d825_3.</Citation></Reference><Reference><Citation>Moustsen-Helms I.R., Bager P., Larsen T.G., Møller F.T., Vestergaard L.S., Rasmussen M., Hansen C.H., Christiansen L.E., Gubbels S., Trebbien R., et al. Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: A nationwide observational study. Lancet Infect. Dis. 2024;24:964–973. doi: 10.1016/S1473-3099(24)00220-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(24)00220-2</ArticleId><ArticleId IdType="pubmed">38761806</ArticleId></ArticleIdList></Reference><Reference><Citation>de Prost N., Audureau E., Guillon A., Handala L., Préau S., Guigon A., Uhel F., Le Hingrat Q., Delamaire F., Grolhier C., et al. Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variant JN.1 in critically ill COVID-19 patients: A prospective, multicenter cohort study. medRxiv. 2024 doi: 10.1101/2024.03.11.24304075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.03.11.24304075</ArticleId><ArticleId IdType="pmc">PMC11213836</ArticleId><ArticleId IdType="pubmed">38940865</ArticleId></ArticleIdList></Reference><Reference><Citation>Kompaniyets L., Agathis N.T., Nelson J.M., Preston L.E., Ko J.Y., Belay B., Pennington A.F., Danielson M.L., DeSisto C.L., Chevinsky J.R., et al. Underlying Medical Conditions Associated With Severe COVID-19 Illness Among Children. JAMA Netw. Open. 2021;4:e2111182. doi: 10.1001/jamanetworkopen.2021.11182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.11182</ArticleId><ArticleId IdType="pmc">PMC8185607</ArticleId><ArticleId IdType="pubmed">34097050</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoste L., Van Paemel R., Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: A systematic review. Eur. J. Pediatr. 2021;180:2019–2034. doi: 10.1007/s00431-021-03993-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-021-03993-5</ArticleId><ArticleId IdType="pmc">PMC7890544</ArticleId><ArticleId IdType="pubmed">33599835</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  COVID Data Tracker: Health Department-Reported Cases of Multisystem Inflammatory Syndrome in Children (MIS-C) in the United States.  [(accessed on 15 March 2024)]; Available online:  https://covid.cdc.gov/covid-data-tracker/#mis-national-surveillance.</Citation></Reference><Reference><Citation>Davies P., Evans C., Kanthimathinathan H.K., Lillie J., Brierley J., Waters G., Johnson M., Griffiths B., du Pre P., Mohammad Z., et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: A multicentre observational study. Lancet Child Adolesc. Health. 2020;4:669–677. doi: 10.1016/S2352-4642(20)30215-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(20)30215-7</ArticleId><ArticleId IdType="pmc">PMC7347350</ArticleId><ArticleId IdType="pubmed">32653054</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambrano L.D., Newhams M.M., Olson S.M., Halasa N.B., Price A.M., Orzel A.O., Young C.C., Boom J.A., Sahni L.C., Maddux A.B., et al. BNT162b2 mRNA Vaccination against Coronavirus Disease 2019 is Associated With a Decreased Likelihood of Multisystem Inflammatory Syndrome in Children Aged 5–18 Years—United States, July 2021–April 2022. Clin. Infect. Dis. 2022;76:e90–e100. doi: 10.1093/cid/ciac637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac637</ArticleId><ArticleId IdType="pmc">PMC9384630</ArticleId><ArticleId IdType="pubmed">35924406</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy M., Recher M., Hubert H., Javouhey E., Flechelles O., Leteurtre S., Angoulvant F. Multisystem Inflammatory Syndrome in Children by COVID-19 Vaccination Status of Adolescents in France. JAMA. 2022;327:281–283. doi: 10.1001/jama.2021.23262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.23262</ArticleId><ArticleId IdType="pmc">PMC8689418</ArticleId><ArticleId IdType="pubmed">34928295</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias M.D., Truong D.T., Oster M.E., Trachtenberg F.L., Mu X., Jone P.N., Mitchell E.C., Dummer K.B., Sexson Tejtel S.K., Osakwe O., et al. Examination of Adverse Reactions after COVID-19 Vaccination among Patients with a History of Multisystem Inflammatory Syndrome in Children. JAMA Netw. Open. 2023;6:e2248987. doi: 10.1001/jamanetworkopen.2022.48987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.48987</ArticleId><ArticleId IdType="pmc">PMC9857632</ArticleId><ArticleId IdType="pubmed">36595296</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipschuetz M., Guedalia J., Cohen S.M., Sompolinsky Y., Shefer G., Melul E., Ergaz-Shaltiel Z., Goldman-Wohl D., Yagel S., Calderon-Margalit R., et al. Maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization. Nat. Med. 2023;29:1155–1163. doi: 10.1038/s41591-023-02270-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02270-2</ArticleId><ArticleId IdType="pubmed">36959421</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardemil C.V., Cao Y., Posavad C.M., Badell M.L., Bunge K., Mulligan M.J., Parameswaran L., Olson-Chen C., Novak R.M., Brady R.C., et al. Maternal COVID-19 Vaccination and Prevention of Symptomatic Infection in Infants. Pediatrics. 2024;153:e2023064252. doi: 10.1542/peds.2023-064252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2023-064252</ArticleId><ArticleId IdType="pmc">PMC10904887</ArticleId><ArticleId IdType="pubmed">38332733</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgensen S.C.J., Hernandez A., Fell D.B., Austin P.C., D’Souza R., Guttmann A., Brown K.A., Buchan S.A., Gubbay J.B., Nasreen S., et al. Maternal mRNA COVID-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants: Test negative design study. BMJ. 2023;380:e074035. doi: 10.1136/bmj-2022-074035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-074035</ArticleId><ArticleId IdType="pmc">PMC9903336</ArticleId><ArticleId IdType="pubmed">36754426</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  COVID-19 Vaccines While Pregnant or Breastfeeding.  [(accessed on 15 March 2024)]; Available online:  https://www.cdc.gov/covid/vaccines/pregnant-or-breastfeeding.html?CDC_AAref_Val=https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html.</Citation></Reference><Reference><Citation>Ludvigsson J.F. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19. Acta Paediatr. 2021;110:914–921. doi: 10.1111/apa.15673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.15673</ArticleId><ArticleId IdType="pmc">PMC7753397</ArticleId><ArticleId IdType="pubmed">33205450</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann P., Pittet L.F., Curtis N. How common is long COVID in children and adolescents? Pediatr. Infect. Dis. J. 2021;40:e482–e487. doi: 10.1097/INF.0000000000003328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003328</ArticleId><ArticleId IdType="pmc">PMC8575095</ArticleId><ArticleId IdType="pubmed">34870392</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnusson K., Kristoffersen D.T., Dell’Isola A., Kiadaliri A., Turkiewicz A., Runhaar J., Bierma-Zeinstra S., Englund M., Magnus P.M., Kinge J.M. Post-COVID medical complaints following infection with SARS-CoV-2 Omicron vs Delta variants. Nat. Commun. 2022;13:7363. doi: 10.1038/s41467-022-35240-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-35240-2</ArticleId><ArticleId IdType="pmc">PMC9709355</ArticleId><ArticleId IdType="pubmed">36450749</ArticleId></ArticleIdList></Reference><Reference><Citation>A World First: Effect of Covid Reinfection on People Living with Long Covid.  [(accessed on 20 August 2024)].  Available online:  https://www.longcovidkids.org/post/a-world-first-effect-of-covid-reinfection-on-people-living-with-long-covid.</Citation></Reference><Reference><Citation>Rayner D.G., Wang E., Su C., Patel O.D., Aleluya S., Giglia A., Zhu E., Siddique M. Risk factors for long COVID in children and adolescents: A systematic review and meta-analysis. World J. Pediatr. 2024;20:133–142. doi: 10.1007/s12519-023-00765-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12519-023-00765-z</ArticleId><ArticleId IdType="pubmed">38055113</ArticleId></ArticleIdList></Reference><Reference><Citation>Osmanov I.M., Spiridonova E., Bobkova P., Gamirova A., Shikhaleva A., Andreeva M., Blyuss O., El-Taravi Y., DunnGalvin A., Comberiati P., et al. Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study. Eur. Respir. J. 2022;59:2101341. doi: 10.1183/13993003.01341-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01341-2021</ArticleId><ArticleId IdType="pmc">PMC8576804</ArticleId><ArticleId IdType="pubmed">34210789</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiss R., Wagner A., Tan L., Schmidt S., Regensburger A.P., Ewert F., Mammadova D., Buehler A., VogelClaussen J., Voskrebenzev A., et al. Persisting pulmonary dysfunction in pediatric post-acute COVID-19. medRxiv. 2022 doi: 10.2139/ssrn.4022232.</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.4022232</ArticleId></ArticleIdList></Reference><Reference><Citation>Shmueli E., Bar-On O., Amir B., Mei-Zahav M., Stafler P., Levine H., Steuer G., Rothschild B., Tsviban L., Amitai N., et al. Pulmonary Evaluation in Children with Post-COVID-19 Condition Respiratory Symptoms: A Prospective Cohort Study. J. Clin. Med. 2023;12:6891. doi: 10.3390/jcm12216891.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12216891</ArticleId><ArticleId IdType="pmc">PMC10648595</ArticleId><ArticleId IdType="pubmed">37959356</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Ayuzo Del Valle N.C., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A., Villapol S. Long-COVID in children and adolescents: A systematic review and meta-analyses. Sci. Rep. 2022;12:9950. doi: 10.1038/s41598-022-13495-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-13495-5</ArticleId><ArticleId IdType="pmc">PMC9226045</ArticleId><ArticleId IdType="pubmed">35739136</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaxman S., Whittaker C., Semenova E., Rashid T., Parks R.M., Blenkinsop A., Unwin H.J.T., Mishra S., Bhatt S., Gurdasani D., et al. Assessment of COVID-19 as the Underlying Cause of Death among Children and Young People Aged 0 to 19 Years in the US. JAMA Netw. Open. 2023;6:e2253590. doi: 10.1001/jamanetworkopen.2022.53590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.53590</ArticleId><ArticleId IdType="pmc">PMC9887489</ArticleId><ArticleId IdType="pubmed">36716029</ArticleId></ArticleIdList></Reference><Reference><Citation>Piroth L., Cottenet J., Mariet A.S., Bonniaud P., Blot M., Tubert-Bitter P., Quantin C. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: A nationwide, population-based retrospective cohort study. Lancet Respir. Med. 2021;9:251–259. doi: 10.1016/S2213-2600(20)30527-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30527-0</ArticleId><ArticleId IdType="pmc">PMC7832247</ArticleId><ArticleId IdType="pubmed">33341155</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC)  Weekly U.S. Influenza Surveillance Report, Updated Week Ending March 4.  [(accessed on 6 March 2023)];2023  Available online:  https://www.cdc.gov/flu/weekly/index.htm.</Citation></Reference><Reference><Citation>UK Health Security Agency  Weekly National Influenza and COVID-19 Surveillance Report Week 10 Report (up to Week 9 Data), 09 March 2023.  [(accessed on 20 August 2024)]; Available online:  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1141346/Weekly_Flu_and_COVID-19_report_w10.pdf.</Citation></Reference><Reference><Citation>UK Health Security Agency  National Influenza and COVID-19 Surveillance Report Week 11 Report (up to Week 10 Data), 14 March 2024.  [(accessed on 20 August 2024)]; Available online:  https://assets.publishing.service.gov.uk/media/65f2d8adaf6c1a001af65792/Weekly-flu-and-COVID-19-surveillance-report-week-11.pdf.</Citation></Reference><Reference><Citation>Rezaee D., Bakhtiari S., Jalilian F.A., Doosti-Irani A., Asadi F.T., Ansari N. Coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus during the COVID-19 pandemic. Arch. Virol. 2023;168:53. doi: 10.1007/s00705-022-05628-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-022-05628-y</ArticleId><ArticleId IdType="pmc">PMC9825093</ArticleId><ArticleId IdType="pubmed">36609722</ArticleId></ArticleIdList></Reference><Reference><Citation>Malveste Ito C.R., Moreira A.L.E., Silva P., Santos M.O., Santos A.P.D., Rezio G.S., Brito P.N., Rezende A.P.C., Fonseca J.G., Peixoto F.A.O., et al. Viral Coinfection of Children Hospitalized with Severe Acute Respiratory Infections during COVID-19 Pandemic. Biomedicines. 2023;11:1402. doi: 10.3390/biomedicines11051402.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11051402</ArticleId><ArticleId IdType="pmc">PMC10216660</ArticleId><ArticleId IdType="pubmed">37239073</ArticleId></ArticleIdList></Reference><Reference><Citation>Steponaviciene A., Burokiene S., Ivaskeviciene I., Staceviciene I., Vaiciuniene D., Jankauskiene A. Influenza and Respiratory Syncytial Virus Infections in Pediatric Patients during the COVID-19 Pandemic: A Single-Center Experience. Children. 2023;10:126. doi: 10.3390/children10010126.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/children10010126</ArticleId><ArticleId IdType="pmc">PMC9856748</ArticleId><ArticleId IdType="pubmed">36670676</ArticleId></ArticleIdList></Reference><Reference><Citation>Musuuza J.S., Watson L., Parmasad V., Putman-Buehler N., Christensen L., Safdar N. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis. PLoS ONE. 2021;16:e0251170. doi: 10.1371/journal.pone.0251170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0251170</ArticleId><ArticleId IdType="pmc">PMC8101968</ArticleId><ArticleId IdType="pubmed">33956882</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregianini T.S., Salvato R.S., Baethgen L.F., Piazza C.F., Barcellos R.B., Godinho F.M., da Veiga A.B.G. Influenza A(H3N2) infection followed by separate COVID-19 infection. Rev. Panam. Salud Publica. 2023;47:e61. doi: 10.26633/RPSP.2023.61.</Citation><ArticleIdList><ArticleId IdType="doi">10.26633/RPSP.2023.61</ArticleId><ArticleId IdType="pmc">PMC10100996</ArticleId><ArticleId IdType="pubmed">37066129</ArticleId></ArticleIdList></Reference><Reference><Citation>Krumbein H., Kummel L.S., Fragkou P.C., Tholken C., Hunerbein B.L., Reiter R., Papathanasiou K.A., Renz H., Skevaki C. Respiratory viral co-infections in patients with COVID-19 and associated outcomes: A systematic review and meta-analysis. Rev. Med. Virol. 2023;33:e2365. doi: 10.1002/rmv.2365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2365</ArticleId><ArticleId IdType="pmc">PMC9347814</ArticleId><ArticleId IdType="pubmed">35686619</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou B., Ma D., Li Y., Qiu L., Chen Y., Hao Y., Luo X., Shu S. Are They Just Two Children COVID-19 Cases Confused With Flu? Front. Pediatr. 2020;8:341. doi: 10.3389/fped.2020.00341.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2020.00341</ArticleId><ArticleId IdType="pmc">PMC7291778</ArticleId><ArticleId IdType="pubmed">32582598</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakuya F., Okubo H., Fujiyasu H., Wakabayashi I., Syouji M., Kinebuchi T. The First Pediatric Patients with Coronavirus Disease 2019 (COVID-19) in Japan: Risk of Co-Infection with Other Respiratory Viruses. Jpn. J. Infect. Dis. 2020;73:377–380. doi: 10.7883/yoken.JJID.2020.181.</Citation><ArticleIdList><ArticleId IdType="doi">10.7883/yoken.JJID.2020.181</ArticleId><ArticleId IdType="pubmed">32475878</ArticleId></ArticleIdList></Reference><Reference><Citation>Grohskopf L.A., Blanton L.H., Ferdinands J.M., Chung J.R., Broder K.R., Talbot H.K. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023–2024 Influenza Season. MMWR Recomm. Rep. 2023;72:1–25. doi: 10.15585/mmwr.rr7202a1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.rr7202a1</ArticleId><ArticleId IdType="pubmed">39197095</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccines and Related Biological Products Advisory Committee  Vaccines and Related Biological Products Advisory Committee Meeting January 26.  [(accessed on 20 August 2024)];2023  Available online:  https://www.fda.gov/media/165307/download.</Citation></Reference><Reference><Citation>World Health Organization  SAGE Updates COVID-19 Vaccination Guidance.  [(accessed on 15 March 2023)].  Available online:  https://web.archive.org/web/20240520045312/https://www.who.int/news/item/28-03-2023-sage-updates-covid-19-vaccination-guidance.</Citation></Reference><Reference><Citation>World Health Organization  From Emergency Response to Long-Term COVID-19 Disease Management: Sustaining Gains Made during the COVID-19 Pandemic.  [(accessed on 20 August 2024)].  Available online:  https://www.who.int/publications/i/item/WHO-WHE-SPP-2023.1.</Citation></Reference><Reference><Citation>United States Food and Drug Administration  Coronavirus (COVID-19) Update: FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines.  [(accessed on 20 August 2024)]; Available online:  https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-changes-simplify-use-bivalent-mrna-covid-19-vaccines.</Citation></Reference><Reference><Citation>Chawla N., Tom A., Sen M.S., Sagar R. Psychological impact of COVID-19 on children and adolescents: A systematic review. Indian J. Psychol. Med. 2021;43:294–299. doi: 10.1177/02537176211021789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/02537176211021789</ArticleId><ArticleId IdType="pmc">PMC8327877</ArticleId><ArticleId IdType="pubmed">34385721</ArticleId></ArticleIdList></Reference><Reference><Citation>Panagouli E., Stavridou A., Savvidi C., Kourti A., Psaltopoulou T., Sergentanis T.N., Tsitsika A. School Performance among Children and Adolescents during COVID-19 Pandemic: A Systematic Review. Children. 2021;8:1134. doi: 10.3390/children8121134.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/children8121134</ArticleId><ArticleId IdType="pmc">PMC8700572</ArticleId><ArticleId IdType="pubmed">34943330</ArticleId></ArticleIdList></Reference><Reference><Citation>UNICEF  The State of the World’s Children 2021: On My Mind–Promoting, Protecting and Caring for Children’s Mental Health.  [(accessed on 20 August 2024)].  Available online:  https://www.unicef.org/media/108161/file/SOWC-2021-full-report-English.pdf.</Citation></Reference><Reference><Citation>UNICEF  COVID-19 and Children.  [(accessed on 20 August 2024)].  Available online:  https://data.unicef.org/covid-19-and-children/</Citation></Reference><Reference><Citation>Parekh N., Ali S.H., O’Connor J., Tozan Y., Jones A.M., Capasso A., Foreman J., DiClemente R.J. Food insecurity among households with children during the COVID-19 pandemic: Results from a study among social media users across the United States. Nutr. J. 2021;20:73. doi: 10.1186/s12937-021-00732-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12937-021-00732-2</ArticleId><ArticleId IdType="pmc">PMC8403824</ArticleId><ArticleId IdType="pubmed">34461913</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedro M., Caldas M., Penas J., Marques B. Impact of the COVID-19 Pandemic on Mental Health in Childhood and Adolescence: The Reality of a Portuguese School. Cureus. 2022;14:e29049. doi: 10.7759/cureus.29049.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.29049</ArticleId><ArticleId IdType="pmc">PMC9553202</ArticleId><ArticleId IdType="pubmed">36237798</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Chen H., Zhai S., Zhu Z., Huang S., Zhou X., Pan Y., Meng D., Yang Z., Zhao J., et al. Is returning to school during the COVID-19 pandemic stressful? A study on immediate mental health status of Chinese college students. J. Affect. Disord. 2021;287:261–267. doi: 10.1016/j.jad.2021.03.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2021.03.035</ArticleId><ArticleId IdType="pmc">PMC8678118</ArticleId><ArticleId IdType="pubmed">33799046</ArticleId></ArticleIdList></Reference><Reference><Citation>covSPECTRUM  JN.1.  [(accessed on 20 August 2024)].  Available online:  https://cov-spectrum.org/explore/World/AllSamples/from%3D2023-12-01%26to%3D2024-03-15/variants?nextcladePangoLineage=jn.1*&amp;.</Citation></Reference><Reference><Citation>covSPECTRUM  BA.2.86.  [(accessed on 20 August 2024)].  Available online:  https://cov-spectrum.org/explore/World/AllSamples/from%3D2023-12-01%26to%3D2024-03-15/variants?nextcladePangoLineage=ba.2.86*&amp;.</Citation></Reference><Reference><Citation>UK Health Security Agency  Omicron Daily Overview: 21 December 2021.  [(accessed on 20 August 2024)]; Available online:  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1043098/20211221_OS_Daily_Omicron_Overview.pdf.</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control (ECDC)  Update on SARS-CoV-2 Variants: ECDC Assessment of the XBB.1.5 Sub-Lineage.  [(accessed on 20 August 2024)].  Available online:  https://www.ecdc.europa.eu/en/news-events/update-sars-cov-2-variants-ecdc-assessment-xbb15-sub-lineage.</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control  Communicable Disease Threats Report, 10–16 March 2024, Week 11.  [(accessed on 20 August 2024)].  Available online:  https://www.ecdc.europa.eu/sites/default/files/documents/communicable-disease-threats-report-week-11-2024.pdf.</Citation></Reference><Reference><Citation>Schlinkmann K.M., Bakuli A., Karch A., Meyer F., Dreesman J., Monazahian M., Mikolajczyk R. Transmission of respiratory and gastrointestinal infections in German households with children attending child care. Epidemiol. Infect. 2018;146:627–632. doi: 10.1017/S0950268818000316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268818000316</ArticleId><ArticleId IdType="pmc">PMC9134537</ArticleId><ArticleId IdType="pubmed">29478420</ArticleId></ArticleIdList></Reference><Reference><Citation>Langeland N., Jane Cox R. Are low SARS-CoV-2 viral loads in infected children missed by RT-PCR testing? Lancet Reg. Health Eur. 2021;5:100138. doi: 10.1016/j.lanepe.2021.100138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100138</ArticleId><ArticleId IdType="pmc">PMC8159172</ArticleId><ArticleId IdType="pubmed">34075368</ArticleId></ArticleIdList></Reference><Reference><Citation>Eyre D.W., Taylor D., Purver M., Chapman D., Fowler T., Pouwels K.B., Walker A.S., Peto T.E.A. Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants. N. Engl. J. Med. 2022;386:744–756. doi: 10.1056/NEJMoa2116597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116597</ArticleId><ArticleId IdType="pmc">PMC8757571</ArticleId><ArticleId IdType="pubmed">34986294</ArticleId></ArticleIdList></Reference><Reference><Citation>Pajon R., Doria-Rose N.A., Shen X., Schmidt S.D., O’Dell S., McDanal C., Feng W., Tong J., Eaton A., Maglinao M., et al. SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination. N. Engl. J. Med. 2022;386:1088–1091. doi: 10.1056/NEJMc2119912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2119912</ArticleId><ArticleId IdType="pmc">PMC8809504</ArticleId><ArticleId IdType="pubmed">35081298</ArticleId></ArticleIdList></Reference><Reference><Citation>Shingleton J., Dyke S., Herrick A., Finnie T. Understanding the immunological landscape of England during SARS-CoV-2 Omicron variant wave. medRxiv. 2022 doi: 10.1371/journal.pone.0264870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0264870</ArticleId><ArticleId IdType="pmc">PMC9565446</ArticleId><ArticleId IdType="pubmed">36240178</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott P., Haw D., Wang H., Eales O., Walters C.E., Ainslie K.E.C., Atchison C., Fronterre C., Diggle P.J., Page A.J., et al. Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. Science. 2021;374:eabl9551. doi: 10.1126/science.abl9551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abl9551</ArticleId><ArticleId IdType="pmc">PMC10763627</ArticleId><ArticleId IdType="pubmed">34726481</ArticleId></ArticleIdList></Reference><Reference><Citation>Akaishi T., Ishii T. Coronavirus disease 2019 transmission and symptoms in young children during the severe acute respiratory syndrome coronavirus 2 Delta variant and Omicron variant outbreaks. J. Int. Med. Res. 2022;50:3000605221102079. doi: 10.1177/03000605221102079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/03000605221102079</ArticleId><ArticleId IdType="pmc">PMC9150257</ArticleId><ArticleId IdType="pubmed">35619217</ArticleId></ArticleIdList></Reference><Reference><Citation>Chadeau-Hyam M., Wang H., Eales O., Haw D., Bodinier B., Whitaker M., Walters C.E., Ainslie K.E.C., Atchison C., Fronterre C., et al. REACT-1 study round 14: High and increasing prevalence of SARS-CoV-2 infection among school-aged children during September 2021 and vaccine effectiveness against infection in England. medRxiv. 2021 doi: 10.1101/2021.10.14.21264965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.10.14.21264965</ArticleId></ArticleIdList></Reference><Reference><Citation>AGES  Dashboard COVID19-Current Situation Austria.  [(accessed on 17 March 2023)].  Available online:  https://covid19-dashboard.ages.at/</Citation></Reference><Reference><Citation>Giardina J., Bilinski A., Fitzpatrick M.C., Kendall E.A., Linas B.P., Salomon J., Ciaranello A.L. Model-estimated association between simulated US elementary school-related SARS-CoV-2 transmission, mitigation interventions, and vaccine coverage across local incidence levels. JAMA Netw. Open. 2022;5:e2147827. doi: 10.1001/jamanetworkopen.2021.47827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.47827</ArticleId><ArticleId IdType="pmc">PMC8845023</ArticleId><ArticleId IdType="pubmed">35157056</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutzoukas A.E., Zimmerman K.O., Benjamin D.K. School Safety, Masking, and the Delta Variant. Pediatrics. 2021;149:e2021054396. doi: 10.1542/peds.2021-054396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2021-054396</ArticleId><ArticleId IdType="pmc">PMC9645698</ArticleId><ArticleId IdType="pubmed">34873629</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinoli C., La Vecchia C., Raimondi S., Bellerba F., Sasso C., Basso A., Cammarata G., Gandini S. SARS-CoV-2 circulation in the school setting: A systematic review and meta-analysis. medRxiv. 2021 doi: 10.2139/ssrn.3885646.</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.3885646</ArticleId><ArticleId IdType="pmc">PMC9099553</ArticleId><ArticleId IdType="pubmed">35564779</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC)  COVID 19: Schools and Childcare Programs.  [(accessed on 3 September 2022)]; Available online:  https://web.archive.org/web/20231230204152/https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fscience%2Fscience-briefs%2Ftransmission_k_12_schools.html.</Citation></Reference><Reference><Citation>Goldstein E., Lipsitch M., Cevik M. On the effect of age on the transmission of SARS-CoV-2 in households, schools, and the community. J. Infect. Dis. 2021;223:362–369. doi: 10.1093/infdis/jiaa691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa691</ArticleId><ArticleId IdType="pmc">PMC7665686</ArticleId><ArticleId IdType="pubmed">33119738</ArticleId></ArticleIdList></Reference><Reference><Citation>Dattner I., Goldberg Y., Katriel G., Yaari R., Gal N., Miron Y., Ziv A., Sheffer R., Hamo Y., Huppert A. The role of children in the spread of COVID-19: Using household data from Bnei Brak, Israel, to estimate the relative susceptibility and infectivity of children. PLoS Comput. Biol. 2021;17:e1008559. doi: 10.1371/journal.pcbi.1008559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1008559</ArticleId><ArticleId IdType="pmc">PMC7877572</ArticleId><ArticleId IdType="pubmed">33571188</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Bloxham C.J., Hulme K.D., Sinclair J.E., Tong Z.W.M., Steele L.E., Noye E.C., Lu J., Xia Y., Chew K.Y., et al. A meta-analysis on the role of children in severe acute respiratory syndrome coronavirus 2 in household transmission clusters. Clin. Infect. Dis. 2021;72:e1146–e1153. doi: 10.1093/cid/ciaa1825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1825</ArticleId><ArticleId IdType="pmc">PMC7799195</ArticleId><ArticleId IdType="pubmed">33283240</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu V.T., Yousaf A.R., Chang K., Schwartz N.G., McDaniel C.J., Lee S.H., Szablewski C.M., Brown M., Drenzek C.L., Dirlikov E., et al. Household transmission of SARS-CoV-2 from children and adolescents. N. Engl. J. Med. 2021;385:954–956. doi: 10.1056/NEJMc2031915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2031915</ArticleId><ArticleId IdType="pmc">PMC8314736</ArticleId><ArticleId IdType="pubmed">34289272</ArticleId></ArticleIdList></Reference><Reference><Citation>Paget J., Spreeuwenberg P., Charu V., Taylor R.J., Iuliano A.D., Bresee J., Simonsen L., Viboud C., Global Seasonal Influenza-associated Mortality Collaborator Network and GLaMOR Collaborating Teams Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project. J. Glob. Health. 2019;9:020421. doi: 10.7189/jogh.09.020421.</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.09.020421</ArticleId><ArticleId IdType="pmc">PMC6815659</ArticleId><ArticleId IdType="pubmed">31673337</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousaf A.R., Cortese M.M., Taylor A.W., Broder K.R., Oster M.E., Wong J.M., Guh A.Y., McCormick D.W., Kamidani S., Schlaudecker E.P., et al. Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: A surveillance investigation. Lancet Child Adolesc. Health. 2022;6:303–312. doi: 10.1016/S2352-4642(22)00028-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(22)00028-1</ArticleId><ArticleId IdType="pmc">PMC8864018</ArticleId><ArticleId IdType="pubmed">35216660</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof S.Y., Frankland T.B., Slezak J.M., Puzniak L., Ackerson B.K., Jodar L., McLaughlin J.M. Receipt of BNT162b2 Vaccine and COVID-19 Ambulatory Visits in US Children Younger Than 5 Years. JAMA. 2023;330:1282–1284. doi: 10.1001/jama.2023.17473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.17473</ArticleId><ArticleId IdType="pmc">PMC10548295</ArticleId><ArticleId IdType="pubmed">37712905</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC)  Hospitalizations of Children and Adolescents with Laboratory-Confirmed COVID-19—COVID-NET, 14 States, July 2021–January 2022.  [(accessed on 20 August 2024)]; Available online:  https://www.cdc.gov/mmwr/volumes/71/wr/mm7107e4.htm.</Citation></Reference><Reference><Citation>Price A.M., Olson S.M., Patel M.M. BNT162b2 protection against the Omicron variant in children and adolescents. Reply. N. Engl. J. Med. 2022;386:2346. doi: 10.1056/NEJMoa2202826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2202826</ArticleId><ArticleId IdType="pubmed">35544367</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof S.Y., Slezak J.M., Puzniak L., Hong V., Frankland T.B., Xie F., Ackerson B.K., Valluri S.R., Jodar L., McLaughlin J.M. Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: A test-negative, case-control study. Lancet Respir. Med. 2023;11:176–187. doi: 10.1016/S2213-2600(22)00354-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00354-X</ArticleId><ArticleId IdType="pmc">PMC9765328</ArticleId><ArticleId IdType="pubmed">36216013</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof S.Y., Frankland T.B., Puzniak L., Slezak J.M., Hong V., Takhar H., Ogun O.A., Simmons S., Xie F., Zamparo J., et al. BNT162b2 against COVID-19-associated Emergency Department and Urgent Care Visits among Children 5–11 Years of Age: A Test Negative Design. J. Pediatric Infect. Dis. Soc. 2023;12:177–179. doi: 10.1093/jpids/piad005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piad005</ArticleId><ArticleId IdType="pmc">PMC10112675</ArticleId><ArticleId IdType="pubmed">36715070</ArticleId></ArticleIdList></Reference><Reference><Citation>Yung C.F., Pang D., Kam K.Q., Lye D.C., Ong B., Chong C.Y., Tan K.B. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: A population-based cohort study. Lancet Child Adolesc. Health. 2023;7:463–470. doi: 10.1016/S2352-4642(23)00101-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(23)00101-3</ArticleId><ArticleId IdType="pmc">PMC10185330</ArticleId><ArticleId IdType="pubmed">37201540</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin D.Y., Xu Y., Gu Y., Zeng D., Wheeler B., Young H., Moore Z., Sunny S.K. Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: An observational cohort study. Lancet Infect. Dis. 2023;23:1257–1265. doi: 10.1016/S1473-3099(23)00272-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00272-4</ArticleId><ArticleId IdType="pmc">PMC10275621</ArticleId><ArticleId IdType="pubmed">37336222</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamidani S., Rostad C.A., Anderson E.J. COVID-19 vaccine development: A pediatric perspective. Curr. Opin. Pediatr. 2021;33:144–151. doi: 10.1097/MOP.0000000000000978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOP.0000000000000978</ArticleId><ArticleId IdType="pubmed">33278108</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin D.-Y., Xu Y., Gu Y., Zeng D., Wheeler B., Young H., Moore Z., Sunny S.K. Effectiveness of Vaccination and Previous Infection Against Omicron Infection and Severe Outcomes in Children Under 12 Years of Age. medRxiv. 2023 doi: 10.1101/2023.01.18.23284739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.01.18.23284739</ArticleId></ArticleIdList></Reference><Reference><Citation>Tannis A., Englund J.A., Perez A., Harker E.J., Staat M.A., Schlaudecker E.P., Halasa N.B., Stewart L.S., Williams J.V., Michaels M.G., et al. SARS-CoV-2 Epidemiology and COVID-19 mRNA Vaccine Effectiveness Among Infants and Children Aged 6 Months-4 Years-New Vaccine Surveillance Network, United States, July 2022-September 2023. MMWR Morb. Mortal. Wkly. Rep. 2023;72:1300–1306. doi: 10.15585/mmwr.mm7248a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7248a2</ArticleId><ArticleId IdType="pmc">PMC10718202</ArticleId><ArticleId IdType="pubmed">38032834</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency  COVID-19 Medicines.  [(accessed on 20 August 2024)].  Available online:  https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/coronavirus-disease-covid-19/covid-19-medicines.</Citation></Reference><Reference><Citation>Levy M.E., Chilunda V., Heaton P.R., McKeen D., Goldman J.D., Davis R.E., Schandl C.A., Glen W.B., McEwen L.M., Cirulli E.T., et al. XBB.1.5 mRNA COVID-19 Vaccination and Inpatient or Emergency Department Visits Among Adults Infected with SARS-CoV-2 JN.1 and XBB-Lineage Variants. medRxiv. 2024 doi: 10.1101/2024.03.05.24303796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.03.05.24303796</ArticleId></ArticleIdList></Reference><Reference><Citation>Olson S.M., Newhams M.M., Halasa N.B., Price A.M., Boom J.A., Sahni L.C., Pannaraj P.S., Irby K., Walker T.C., Schwartz S.P., et al. Effectiveness of BNT162b2 vaccine against critical Covid-19 in adolescents. N. Engl. J. Med. 2022;386:713–723. doi: 10.1056/NEJMoa2117995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2117995</ArticleId><ArticleId IdType="pmc">PMC8781318</ArticleId><ArticleId IdType="pubmed">35021004</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali K., Berman G., Zhou H., Deng W., Faughnan V., Coronado-Voges M., Ding B., Dooley J., Girard B., Hillebrand W., et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N. Engl. J. Med. 2021;385:2241–2251. doi: 10.1056/NEJMoa2109522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109522</ArticleId><ArticleId IdType="pmc">PMC8385554</ArticleId><ArticleId IdType="pubmed">34379915</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell A.A., Kirsebom F., Stowe J., McOwat K., Saliba V., Ramsay M.E., Lopez-Bernal J., Andrews N., Ladhani S.N. Adolescent vaccination with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine and effectiveness against COVID-19: National test-negative case-control study, England. medRxiv. 2021 doi: 10.1101/2021.12.10.21267408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.10.21267408</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food &amp; Drug Administration  Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children down to 6 Months of Age.  [(accessed on 20 August 2024)]; Available online:  https://public4.pagefreezer.com/browse/FDA/31-01-2024T13:34/https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-covid-19-vaccines-children.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA)  EMA Recommends Approval of Comirnaty and Spikevax COVID-19 Vaccines for Children from 6 Months of Age.  [(accessed on 20 August 2024)].  Available online:  https://www.ema.europa.eu/en/news/ema-recommends-approval-comirnaty-spikevax-covid-19-vaccines-children-6-months-age.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA)  ETF Statement on the Use of the EMA Approved Bivalent Original/Omicron BA.4-5 mRNA Vaccines for Primary Series.  [(accessed on 20 August 2024)].  Available online:  https://www.ema.europa.eu/en/documents/other/etf-statement-use-ema-approved-bivalent-original/omicron-ba4-5-mrna-vaccines-primary-series_en.pdf.</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration  COVID-19 Vaccines.  [(accessed on 20 August 2024)]; Available online:  https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines.</Citation></Reference><Reference><Citation>Chemaitelly H., Ayoub H.H., AlMukdad S., Coyle P., Tang P., Yassine H.M., Al-Khatib H.A., Smatti M.K., Hasan M.R., Al-Kanaani Z., et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. Nat. Commun. 2022;13:3082. doi: 10.1038/s41467-022-30895-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30895-3</ArticleId><ArticleId IdType="pmc">PMC9163167</ArticleId><ArticleId IdType="pubmed">35654888</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbel R., Peretz A., Sergienko R., Friger M., Beckenstein T., Duskin-Bitan H., Yaron S., Hammerman A., Bilenko N., Netzer D. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: A retrospective cohort study. Lancet Infect. Dis. 2023;23:914–921. doi: 10.1016/S1473-3099(23)00122-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00122-6</ArticleId><ArticleId IdType="pmc">PMC10156150</ArticleId><ArticleId IdType="pubmed">37062302</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Ayoub H.H., Faust J.S., Coyle P., Tang P., Hasan M.R., Yassine H.M., Al-Khatib H.A., Thani A.A.A., Al-Kanaani Z., et al. A turning point in COVID-19 severity and fatality during the pandemic: A national cohort study in Qatar. medRxiv. 2023 doi: 10.1136/bmjph-2023-000479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjph-2023-000479</ArticleId></ArticleIdList></Reference><Reference><Citation>United States Food and Drug Administration  Recommendation for the 2023–2024 Formula of COVID-19 Vaccines in the U.S.  [(accessed on 20 August 2024)]; Available online:  https://www.fda.gov/media/169591/download.</Citation></Reference><Reference><Citation>European Medicines Agency  COMIRNATY® SmPC.  [(accessed on 20 August 2024)].  Available online:  https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>European Medicines Agency  Spikevax (Previously COVID-19 Vaccine Moderna) Summary of Product Characteristics.  [(accessed on 20 August 2024)].  Available online:  https://www.ema.europa.eu/en/medicines/human/EPAR/spikevax.</Citation></Reference><Reference><Citation>Novavax  Summary of Product Characteristics: Nuvaxovid Dispersion for Injection.  [(accessed on 20 August 2024)]; Available online:  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1100524/GB_SmPC_Nuvaxovid_August_2022.pdf.</Citation></Reference><Reference><Citation>European Medicines Agency  Summary of Product Characteristics COVID-19 Vaccine Bimervax.  [(accessed on 20 August 2024)].  Available online:  www.ema.europa.eu/en/documents/product-information/bimervax-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>European Medicines Agency  Summary of Product Characteristics COVID-19 Vaccine Janssen.  [(accessed on 20 August 2024)].  Available online:  https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-janssen-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>Toepfner N., von Meissner W.C.G., Strumann C., Drinka D., Stuppe D., Jorczyk M., Moor J., Puschel J., Liss M., von Poblotzki E., et al. Comparative Safety of the BNT162b2 Messenger RNA COVID-19 Vaccine vs Other Approved Vaccines in Children Younger Than 5 Years. JAMA Netw. Open. 2022;5:e2237140. doi: 10.1001/jamanetworkopen.2022.37140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.37140</ArticleId><ArticleId IdType="pmc">PMC9579908</ArticleId><ArticleId IdType="pubmed">36255723</ArticleId></ArticleIdList></Reference><Reference><Citation>Malden D.E., Gee J., Glenn S., Li Z., Mercado C., Ogun O.A., Kim S., Lewin B.J., Ackerson B.K., Jazwa A., et al. Reactions following Pfizer-BioNTech COVID-19 mRNA vaccination and related healthcare encounters among 7,077 children aged 5-11 years within an integrated healthcare system. Vaccine. 2023;41:315–322. doi: 10.1016/j.vaccine.2022.10.079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.10.079</ArticleId><ArticleId IdType="pmc">PMC9630154</ArticleId><ArticleId IdType="pubmed">36351861</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong H.-L., Hu M., Zhou C.K., Lloyd P.C., Amend K.L., Beachler D.C., Secora A., McMahill-Walraven C.N., Lu Y., Wu Y., et al. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: A cohort study in claims databases. Lancet. 2022;399:2191–2199. doi: 10.1016/S0140-6736(22)00791-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00791-7</ArticleId><ArticleId IdType="pmc">PMC9183215</ArticleId><ArticleId IdType="pubmed">35691322</ArticleId></ArticleIdList></Reference><Reference><Citation>Hause A.M., Marquez P., Zhang B., Myers T.R., Gee J., Su J.R., Blanc P.G., Thomas A., Thompson D., Shimabukuro T.T., et al. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years-United States, August 31–October 23, 2022. MMWR Morb. Mortal. Wkly. Rep. 2022;71:1401–1406. doi: 10.15585/mmwr.mm7144a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7144a3</ArticleId><ArticleId IdType="pmc">PMC9639436</ArticleId><ArticleId IdType="pubmed">36327162</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  Vaccination Trends—Children.  [(accessed on 20 August 2024)]; Available online:  https://www.cdc.gov/respiratory-viruses/data/vaccination-trends-children.html?CDC_AAref_Val=https://www.cdc.gov/respiratory-viruses/data-research/dashboard/vaccination-trends-children.html.</Citation></Reference><Reference><Citation>Temsah M.H., Alhuzaimi A.N., Aljamaan F., Bahkali F., Al-Eyadhy A., Alrabiaah A., Alhaboob A., Bashiri F.A., Alshaer A., Temsah O., et al. Parental Attitudes and Hesitancy About COVID-19 vs. Routine Childhood Vaccinations: A National Survey. Front. Public Health. 2021;9:752323. doi: 10.3389/fpubh.2021.752323.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2021.752323</ArticleId><ArticleId IdType="pmc">PMC8548678</ArticleId><ArticleId IdType="pubmed">34722451</ArticleId></ArticleIdList></Reference><Reference><Citation>Patone M., Mei X.W., Handunnetthi L., Dixon S., Zaccardi F., Shankar-Hari M., Watkinson P., Khunti K., Harnden A., Coupland C.A.C., et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat. Med. 2022;28:410–422. doi: 10.1038/s41591-021-01630-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01630-0</ArticleId><ArticleId IdType="pmc">PMC8863574</ArticleId><ArticleId IdType="pubmed">34907393</ArticleId></ArticleIdList></Reference><Reference><Citation>BioNTech  Summary of Product Characteristics: Comirnaty 10 Micrograms/Dose Concentrate for Dispersion for Injection.  [(accessed on 20 August 2024)]; Available online:  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1098216/SPC_COMIRNATY_10_mcg_orange_cap_clean.pdf.</Citation></Reference><Reference><Citation>World Health Organization  Ten Threats to Global Health in 2019.  [(accessed on 15 March 2024)].  Available online:  https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019.</Citation></Reference><Reference><Citation>Kassianos G., Puig-Barbera J., Dinse H., Teufel M., Tureci O., Pather S. Addressing COVID-19 vaccine hesitancy. Drugs Context. 2022;11:2021-12-3. doi: 10.7573/dic.2021-12-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.7573/dic.2021-12-3</ArticleId><ArticleId IdType="pmc">PMC9225513</ArticleId><ArticleId IdType="pubmed">35814493</ArticleId></ArticleIdList></Reference><Reference><Citation>Dopelt K., Abudin A., Yukther S., Shmukler T., Davidovitch N. The Association between Levels of Trust in the Healthcare System and Influenza Vaccine Hesitancy among College Students in Israel. Vaccines. 2023;11:1728. doi: 10.3390/vaccines11111728.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11111728</ArticleId><ArticleId IdType="pmc">PMC10674655</ArticleId><ArticleId IdType="pubmed">38006060</ArticleId></ArticleIdList></Reference><Reference><Citation>Solís Arce J.S., Warren S.S., Meriggi N.F., Scacco A., McMurry N., Voors M., Syunyaev G., Malik A.A., Aboutajdine S., Adeojo O., et al. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. Nat. Med. 2021;27:1385–1394. doi: 10.1038/s41591-021-01454-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01454-y</ArticleId><ArticleId IdType="pmc">PMC8363502</ArticleId><ArticleId IdType="pubmed">34272499</ArticleId></ArticleIdList></Reference><Reference><Citation>Ten Kate J., Koster W., Van der Waal J. “Following your gut” or “questioning the scientific evidence”: Understanding vaccine skepticism among more-educated Dutch parents. J. Health Soc. Behav. 2021;62:85–99. doi: 10.1177/0022146520986118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0022146520986118</ArticleId><ArticleId IdType="pmc">PMC7944425</ArticleId><ArticleId IdType="pubmed">33533672</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruell H., Vanshylla K., Tober-Lau P., Hillus D., Schommers P., Lehmann C., Kurth F., Sander L.E., Klein F. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat. Med. 2022;28:477–480. doi: 10.1038/s41591-021-01676-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01676-0</ArticleId><ArticleId IdType="pmc">PMC8767537</ArticleId><ArticleId IdType="pubmed">35046572</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou J., Kurhade C., Patel S., Kitchin N., Tompkins K., Cutler M., Cooper D., Yang Q., Cai H., Muik A., et al. Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine. bioRxiv. 2022 doi: 10.1101/2022.11.17.516898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.11.17.516898</ArticleId><ArticleId IdType="pmc">PMC9891359</ArticleId><ArticleId IdType="pubmed">36734885</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R., Rowley E.A.K., DeSilva M.B., Dascomb K., Irving S.A., Klein N.P., Grannis S.J., Ong T.C., Weber Z.A., Fleming-Dutra K.E., et al. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines against COVID-19-Associated Hospitalization Among Adults Aged &gt;/=18 Years with Immunocompromising Conditions-VISION Network, September 2023–February 2024. MMWR Morb. Mortal. Wkly. Rep. 2024;73:271–276. doi: 10.15585/mmwr.mm7312a5.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7312a5</ArticleId><ArticleId IdType="pmc">PMC10986819</ArticleId><ArticleId IdType="pubmed">38547037</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Coyle P., Kacem M.A.B., Ayoub H.H., Tang P., Hasan M.R., Yassine H.M., Thani A.A.A., Al-Kanaani Z., Al-Kuwari E., et al. Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant. medRxiv. 2024 doi: 10.1093/jtm/taae053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jtm/taae053</ArticleId><ArticleId IdType="pmc">PMC11149714</ArticleId><ArticleId IdType="pubmed">38591115</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin D.R., Higdon M.M., Abu-Raddad L.J., Andrews N., Araos R., Goldberg Y., Groome M.J., Huppert A., O’Brien K.L., Smith P.G., et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: Results of a systematic review and meta-regression. Lancet. 2022;399:924–944. doi: 10.1016/S0140-6736(22)00152-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00152-0</ArticleId><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>Covid-Forecasting Team Past SARS-CoV-2 infection protection against re-infection: A systematic review and meta-analysis. Lancet. 2023;401:833–842. doi: 10.1016/S0140-6736(22)02465-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02465-5</ArticleId><ArticleId IdType="pmc">PMC9998097</ArticleId><ArticleId IdType="pubmed">36930674</ArticleId></ArticleIdList></Reference><Reference><Citation>Dube E., Gagnon D., Pelletier C. COVID-19 vaccination in 5-11 years old children: Drivers of vaccine hesitancy among parents in Quebec. Hum. Vaccin. Immunother. 2022;18:2028516. doi: 10.1080/21645515.2022.2028516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2028516</ArticleId><ArticleId IdType="pmc">PMC8993071</ArticleId><ArticleId IdType="pubmed">35103550</ArticleId></ArticleIdList></Reference><Reference><Citation>Galanis P., Vraka I., Siskou O., Konstantakopoulou O., Katsiroumpa A., Kaitelidou D. Willingness, refusal and influential factors of parents to vaccinate their children against the COVID-19: A systematic review and meta-analysis. Prev. Med. 2022;157:106994. doi: 10.1016/j.ypmed.2022.106994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ypmed.2022.106994</ArticleId><ArticleId IdType="pmc">PMC8861629</ArticleId><ArticleId IdType="pubmed">35183597</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddinger J.L., Levine D., Charness G. Can targeted messages reduce COVID-19 vaccination hesitancy? A randomized trial. Prev. Med. Rep. 2022;29:101903. doi: 10.1016/j.pmedr.2022.101903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pmedr.2022.101903</ArticleId><ArticleId IdType="pmc">PMC9272666</ArticleId><ArticleId IdType="pubmed">35844628</ArticleId></ArticleIdList></Reference><Reference><Citation>Omer S.B., Benjamin R.M., Brewer N.T., Buttenheim A.M., Callaghan T., Caplan A., Carpiano R.M., Clinton C., DiResta R., Elharake J.A., et al. Promoting COVID-19 vaccine acceptance: Recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. Lancet. 2021;398:2186–2192. doi: 10.1016/S0140-6736(21)02507-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02507-1</ArticleId><ArticleId IdType="pmc">PMC8592561</ArticleId><ArticleId IdType="pubmed">34793741</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson E.L. Recommended solutions to the barriers to immunization in children and adults. Mo. Med. 2014;111:344–348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6179470</ArticleId><ArticleId IdType="pubmed">25211867</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>